In silico evaluation for the potential naturally available drugs for breast cancer

References

• Jemal A, Siegel R, Ward E, et al. Cancer stastistics. CA Cancer J Clin 2006;56:106–30
   Google Scholar
• National Cancer Institute. Probability of breast cancer in American women. Available from: http://www.cancer.gov/ cancer topics/factsheet/Detection/Probability-breast-cancer [last accessed 4 Nov 2013]
   Google Scholar
• Frlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893–917
   Google Scholar
• National Cancer Institute. Breast cancer. Available from: http://www.cancer.gov/cancertopics/types/breast [last accessed 4 Nov 2013]
   Google Scholar
• James R, Thrivenik K, krishnamoorthy L, et al. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer. Indian J Med Res 2011;133:70–5
   Google Scholar
• Natasha TR Zora K, Dragica NV. Cross-talk between ER and Her 2 in breast carcinoma. Arch Oncol 2006;14:146–50
   Google Scholar
• Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12
   PubMed Web of Science ®Google Scholar
• Dean-Colomb W, Esteva FJ. Her2-Positive breast cancer: herceptin and beyond. Eur J Cancer 2008;44:2806–12
   PubMed Web of Science ®Google Scholar
• Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens:comparision of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000;53:374–81
   PubMed Web of Science ®Google Scholar
• Menard S,Casalini P, Campiglio M, et al. Her2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001;12:S15–19
   PubMedGoogle Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb B-related gene in a human mammary Carcinoma. Science 1985;229:974–6
   PubMed Web of Science ®Google Scholar
• Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61:1–13
   PubMed Web of Science ®Google Scholar
• Hung MC, Lau Y-K. Basic Science of HER 2/neu: a review. Semin Oncol 1999;26:51–9
   PubMed Web of Science ®Google Scholar
• Slamon DJ. Proto-oncogenes and humancancers. N Engl J Med 1987;317:955–7
   PubMed Web of Science ®Google Scholar
• Carraway KL III, Weber JL, Unger MJ, et al. Neuregulin-2 a new ligand of erbB3/erbB4-receptor tyrosine kinase. Nature 1997;387:512–16
   PubMed Web of Science ®Google Scholar
• Linnea DR, Duane KJ, Dennis JS, Benita SK. Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and pI 85 protein expression in human breast cancer cell lines. Cancer Res 1990;50:3947–51
   Google Scholar
• Graus-Porta D, Beerli RR, Dalya JM, Hynes NE. ErbB-2 the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647–55
   PubMed Web of Science ®Google Scholar
• Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99–110
   PubMed Web of Science ®Google Scholar
• Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis of HER 1/EGFR, HER 2, HER 3, and HER 4 in 278 breast cancer patients. Breast Cancer Res 2008;10:R2
   PubMed Web of Science ®Google Scholar
• Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma. A systematic review. Radiother Oncol 2009;90:1–13
   PubMed Web of Science ®Google Scholar
• Kirby RM, Basit A, Manimaran N. Patient choice significantly affects mastectomy rates in the treatment of breast cancer. Int Semin Surg Oncol 2008;5:20–2
   Google Scholar
• Winzer KJ, Sauerberi W, Braun M, et al. German Breast Cancer Study Group (GBSG). Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2X2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2010;46:95–101
   Google Scholar
• Siponen ET, Vaalavirata L, Joensuu H, et al. Ipsilateral breast recurrence after breast conserving surgery in patients with small (≤ cm) breast cancer treated with modern adjuvant therapies. Eur J Surg Oncol 2011;37:15–31
   Google Scholar
• Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432–6
   PubMed Web of Science ®Google Scholar
• Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a north american trial. J Clin Oncol 2002;20:3386–95
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20
   PubMed Web of Science ®Google Scholar
• Aas T, Børresen A-L, Geisler S, et al. Specific P53 mutations are associated withde novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811–14
   PubMed Web of Science ®Google Scholar
• Ahmad N, Feyes DK, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89:1881--6
   PubMed Web of Science ®Google Scholar
• Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. JCO November 1998;11:3502–8
   Google Scholar
• Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089--93
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733–43
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbb-1- and/or erbb-2-positive, estrogen receptor–positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–16
   Google Scholar
• Di Leo A, Gancberg D, Larsimont D, et al. HER-2 Amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107–16
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76
   PubMed Web of Science ®Google Scholar
• Zhouy Z-T, Yangy Y, Ge J-P. The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters. Carcinogenesis 2006;27:826–32
   Google Scholar
• Nakayama A, Takagi S, Yusa T, et al. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model. J Cancer 2013;4:557–65
   PubMedGoogle Scholar
• Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the royal marsden randomized, double-blinded tamoxifen breast cancer prevention trial. JNCI J Natl Cancer Inst 2007;99:283–90
   Google Scholar
• Goud KI, Dayakar S, Vijayalaxmi K, et al. Evaluation of HER-2/neu status in breast cancer specimens using Immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res 2012;135:312–17
   Google Scholar